ResMed Inc. logo

ResMed Inc.

RMD

NYSEHealthcareMedical - Instruments & Supplies

Previous close

$231.52

+$3.08 · +1.35%

Aug 21, 4:00 PM ET

RMD company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Buy

Favorable setup — positive multi-factor alignment

Valuation

99

Deep Value

Momentum

40

Weakening

Sentiment

72

Bullish

Risk resilience

57

Elevated Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

ResMed Inc. is a leading global medical technology enterprise engaged in the creation, production, distribution, and marketing of healthcare devices and connected digital solutions. The company operates through two primary segments: Sleep and Respiratory Care, and Software as a Service. Its extensive product range addresses a variety of respiratory disorders, encompassing advanced medical and consumer technologies, ventilation devices, diagnostic equipment, mask systems for both clinical and personal use, headgear, and related accessories, alongside dental devices. ResMed also provides sophisticated cloud-based informatics to enhance patient management and operational efficiency. Notable software offerings in its respiratory portfolio include AirView, for remote device monitoring and setting adjustments; myAir, a personalized application designed to support sleep apnea patients with education and troubleshooting for better engagement and adherence; and U-Sleep, a compliance tracking platform for home medical equipment providers. Complementing these are connectivity modules and Propeller solutions. Furthermore, ResMed offers a robust suite of out-of-hospital software. This includes Brightree, a business management platform for various home care service providers (e.g., HME, pharmacy, infusion, orthotics, prosthetics); MatrixCare, providing care management for senior living, skilled nursing, and hospice organizations; and HEALTHCAREfirst, which supplies electronic health records, billing, coding services, and analytics for home health and hospice agencies. ResMed distributes its offerings primarily to sleep clinics, home healthcare dealers, and hospitals via a global network of distributors and a direct sales force, serving approximately 140 countries. Founded in 1989, the company's headquarters are located in San Diego, California.

Industry
Medical - Instruments & Supplies
Sector
Healthcare
Headquarters
US
CEO
Michael J. Farrell
Listed since
Jun 2, 1995
Employees
11,370

Market position

Day range

Current $231.52

52-week range

Current $231.52

Open
$229.44
Previous close
$228.44
Volume
925.81K
0.62× average
Average volume
1.5M
Average daily volume
Market cap
33.58B USD
Beta
0.75
Market reference 1
50-day average
$206.94
+11.88% above average
200-day average
$229.13
+1.04% above average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
27.56B USD
P/E (TTM)
22.18×
P/B (TTM)
5.09×
P/S (TTM)
5.94×
EV / EBITDA
12.84×
Earnings yield
5.40%
Free cash flow yield
5.85%
Dividend yield
1.06%

Profitability & efficiency

Gross margin
61.16%
Operating margin
33.48%
Net margin
26.94%
Return on equity
23.13%
Return on assets
16.99%
Return on invested capital
19.11%

Financial health

Debt / equity
0.13×
Current ratio
3.1×

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends65%49%33%17%Gross margin, FY2022: 56.57%Gross margin, FY2023: 55.78%Gross margin, FY2024: 56.67%Gross margin, FY2025: 59.36%Gross margin, FY2026: 61.16%Operating margin, FY2022: 27.96%Operating margin, FY2023: 26.80%Operating margin, FY2024: 28.17%Operating margin, FY2025: 32.75%Operating margin, FY2026: 33.48%Net margin, FY2022: 21.78%Net margin, FY2023: 21.25%Net margin, FY2024: 21.79%Net margin, FY2025: 27.22%Net margin, FY2026: 26.94%FY2022FY2023FY2024FY2025FY2026
Gross margin FY2022 56.57%. Gross margin FY2023 55.78%. Gross margin FY2024 56.67%. Gross margin FY2025 59.36%. Gross margin FY2026 61.16%. Operating margin FY2022 27.96%. Operating margin FY2023 26.80%. Operating margin FY2024 28.17%. Operating margin FY2025 32.75%. Operating margin FY2026 33.48%. Net margin FY2022 21.78%. Net margin FY2023 21.25%. Net margin FY2024 21.79%. Net margin FY2025 27.22%. Net margin FY2026 26.94%.

Income trends

Revenue

5.65B USD+9.85%

Operating income

1.89B USD+12.30%

Net income

1.52B USD+8.75%
Income trends across reported periods6.14B USD4.19B USD2.24B USD292.04M USDRevenue, FY2022: 3.58B USDRevenue, FY2023: 4.22B USDRevenue, FY2024: 4.69B USDRevenue, FY2025: 5.15B USDRevenue, FY2026: 5.65B USDOperating income, FY2022: 1B USDOperating income, FY2023: 1.13B USDOperating income, FY2024: 1.32B USDOperating income, FY2025: 1.69B USDOperating income, FY2026: 1.89B USDNet income, FY2022: 779.44M USDNet income, FY2023: 897.56M USDNet income, FY2024: 1.02B USDNet income, FY2025: 1.4B USDNet income, FY2026: 1.52B USDFY2022FY2023FY2024FY2025FY2026
Revenue FY2022 3.58B USD. Revenue FY2023 4.22B USD. Revenue FY2024 4.69B USD. Revenue FY2025 5.15B USD. Revenue FY2026 5.65B USD. Operating income FY2022 1B USD. Operating income FY2023 1.13B USD. Operating income FY2024 1.32B USD. Operating income FY2025 1.69B USD. Operating income FY2026 1.89B USD. Net income FY2022 779.44M USD. Net income FY2023 897.56M USD. Net income FY2024 1.02B USD. Net income FY2025 1.4B USD. Net income FY2026 1.52B USD.
Metric (USD)FY2026FY2025FY2024FY2023FY2022
Revenue5.65B USD5.15B USD4.69B USD4.22B USD3.58B USD
Cost of goods sold2.2B USD2.09B USD2.03B USD1.87B USD1.55B USD
Gross profit3.46B USD3.05B USD2.66B USD2.36B USD2.02B USD
Research and development378.29M USD331.28M USD307.53M USD287.64M USD253.58M USD
Selling, general, and administrative817.39M USD991.02M USD917.14M USD874M USD739.37M USD
Operating expenses1.57B USD1.37B USD1.34B USD1.22B USD1.02B USD
Interest expense29.03M USD12.61M USD45.71M USD47.38M USD22.31M USD
Depreciation and amortization197.86M USD235.81M USD216.21M USD196.52M USD193.84M USD
Operating income1.89B USD1.69B USD1.32B USD1.13B USD1B USD
Net income1.52B USD1.4B USD1.02B USD897.56M USD779.44M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
82%
9 beats, 1 miss, 1 met estimate
Average EPS surprise
+3.31%
11 comparable reports
Latest EPS result
2.95
Estimate 2.89 · Beat by 2.08%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates3.072.782.492.2Q1 '25BeatQ2 '25MissQ3 '25MetQ4 '25BeatQ1 '26BeatQ2 '26BeatQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Jan 30, 2025: actual 2.43, estimate 2.32, surprise +4.74%, Beat. Q2 2025, reported Apr 23, 2025: actual 2.37, estimate 2.38, surprise -0.42%, Miss. Q3 2025, reported Jul 31, 2025: actual 2.55, estimate 2.55, surprise 0.00%, Met estimate. Q4 2025, reported Oct 30, 2025: actual 2.55, estimate 2.51, surprise +1.59%, Beat. Q1 2026, reported Jan 29, 2026: actual 2.81, estimate 2.74, surprise +2.55%, Beat. Q2 2026, reported Apr 30, 2026: actual 2.86, estimate 2.8, surprise +2.14%, Beat. Q3 2026, reported Aug 6, 2026: actual 2.95, estimate 2.89, surprise +2.08%, Beat. Q4 2026, reported Oct 29, 2026: actual —, estimate 2.69, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates1.52B1.42B1.31B1.21BQ1 '25BeatQ2 '25BeatQ3 '25MetQ4 '25BeatQ1 '26BeatQ2 '26BeatQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Jan 30, 2025: actual 1.28B USD, estimate 1.27B USD, surprise +1.22%, Beat. Q2 2025, reported Apr 23, 2025: actual 1.29B USD, estimate 1.29B USD, surprise +0.28%, Beat. Q3 2025, reported Jul 31, 2025: actual 1.35B USD, estimate 1.35B USD, surprise 0.00%, Met estimate. Q4 2025, reported Oct 30, 2025: actual 1.34B USD, estimate 1.33B USD, surprise +0.17%, Beat. Q1 2026, reported Jan 29, 2026: actual 1.42B USD, estimate 1.4B USD, surprise +1.59%, Beat. Q2 2026, reported Apr 30, 2026: actual 1.43B USD, estimate 1.42B USD, surprise +0.81%, Beat. Q3 2026, reported Aug 6, 2026: actual 1.46B USD, estimate 1.46B USD, surprise +0.16%, Beat. Q4 2026, reported Oct 29, 2026: actual —, estimate 1.39B USD, surprise —, Comparison unavailable.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Analyst price target

Average target

$238.7

3.10% upside
Past 12 months12-month forecast

Price history unavailable

High $300Average $238.7Low $213

Rating distribution

35 ratings
Strong buy00%
Buy1337%
Hold1749%
Sell514%
Strong sell00%

Recent analyst actions

12 institutions
JefferiesmaintainHold

RMD news

Corporate actions

Corporate action history

Stock split

Effective Aug 31, 2010

2:1

Stock split

Effective Oct 3, 2005

2:1

Stock split

Effective Apr 3, 2000

2:1

Stock split

Effective Nov 17, 1998

2:1

RMD peers

ETFs holding RMD

Funds reporting this stock among their holdings, ordered by reported position size.

Continue in GoAI

Research RMD

research.disclaimer